Hi Gays n gals, the train has reached its first destination (resistant). Please proceed to exit door for short term travelers (traders). For longer distance travelers, please stay calm and relax and enjoy surrounding scenery. The train will take a rest for a while before moving on. Meanwhile, be prepared to face some resistance. It may not be as smooth as before form now. 1 remainder to short distance travelers...should you have exited and wanted to come back, be prepared to buy a more expensive ticket later. So, think through before you exit. There are many other travelers waiting outside too, looking for a cheap seat.
Disappointed with their financial growth rate in 2021, it seems to be an endless waiting. They should be OEM low-end medical products and no market competitiveness.
We remain optimistic with the Group's mid to long term prospects underpinned by continuous growing demand from customers in addition to several new products in the pipeline.
Thus, barring any unforeseen circumstances, the Group is expecting the performance for the next financial year to be satisfactory.
@ Jerry87, https://www.youtube.com/watch?v=ic0hwPAACg0 This is the company future growth trend. Do you think it is low-end products ? This is the replacement for the by-pass / balloon for stroke operation.
Referring to my earlier comments dated 25/11, its FY2021 PAT of RM25.3 mil is within expectation, due to the MCO lock-down during the year. However, moving forward, I expect the company to achieve RM35 mil in FY2022, due to its factory expansion is progressing well. Management indicates a 30% growth is achievable. This translates into EPS of 4.6sen or PE of 32.6x. I have to admit that given current increasing interest rate environment, current PE valuation is a bit on a high-side. Anyway, if we can ride through the tide, its 2023 profit should is forecast at around RM50 mil after the full completion of the factory construction then, or a PE of 23x which is fair at current level.
Turnover increased but profit did not increase proportionately. It seems that Supercomal also encountered the same problem before. What is the control problem? It's not the first day that raw material increases happen. Will there be no more problems in the new season?
Author: kiasutrader | Publish date: Thu, 24 Feb 2022, 10:42 AM Supercomnet Technologies Bhd (Trading Buy)
After falling from a recent high of RM2.08 in end-December last year, SCOMNET’s share price – which ended at RM1.53 yesterday – could stage a technical rebound ahead.
With both the RSI and stochastic indicators in the midst of reversing from their oversold positions, the stock will probably climb in tandem.
On the way up, SCOMNET shares are expected to shift towards our resistance thresholds of RM1.71 (R1) and RM1.88 (R2). This translates to upside potentials of 12% and 23%, respectively.
Our stop loss price level is pegged at RM1.39 (or a 9% downside risk).
The group has just announced net profit of RM8.0m (-4% YoY) in 4QFY21, taking full-year net earnings to RM25.3m (+8% YoY) on the back of turnover of RM145.4m (+13% YoY) in FY21.
In the business of manufacturing and assembling advanced high technology wires and cables, SCOMNET derives its revenue mostly from the medical devices (62% of 4QFY21’s sales), industrial (namely electrical appliances & consumer electronics) (27% of sales) and automotive (11% of sales) segments.
With a debt-free balance sheet, SCOMNET is financially backed by cash holdings of RM45.2m and unit trust investments of RM102.3m (both of which added up to 19.4 sen per share) as of end-December 2021.
Hahhaa.... everything is also having potential, promising or not, really have to see the management. If they are really doing business. the price will shine 1 day.
In the transformation stage, management is the most important, but those who attended the AGM meeting could see that they were all old management directors in the traditional industry, and such an organization is exactly what I am worried about, and may not be able to carry out healthcare transformation smoothly in the future.
YouTube link: https://youtu.be/5uzrddDGzso (Eng & Chi subtitles) The Power Talk with Supercomnet Technologies Bhd 神通科技是在近年崛起的医疗器材生产商。这家市值近10亿令吉的马股上市公司受到来自欧美大型上市公司的庇护,过去5年的盈利表现直线上扬,更受到各大机构投资者的青睐。 我有幸前往吉打双溪大年与大股东 -- 薛氏家族及 Eng Chuan Lim 进行了这个深入的专访。究竟这家公司有什么来头,我们且听听大股东们怎么说
The annual report shows that CEO is paid under the similar-sized companies, such low paid OEM plant ,family business ,If you just want to earn dividends I think it's fine BUT development and expansion....best of luck guys
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: The onshore and offshore support services provider for the O&G industry, Steel Hawk Bhd aims to list on the Ace Market!
MQ Trader 2909 views | 2 d ago
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
BobLimm
52 posts
Posted by BobLimm > 2021-12-10 11:13 | Report Abuse
One of their key customers CEO said "We are just getting started..."
https://youtu.be/AVY060ALTVA
Also Scomnet received Supplier of the Year 2021 Award from customer E.